Результаты поиска

Регрессия задушенной миэломы с лечением болезни Гаучера.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

IgG4-related kidney disease complicated with retroperitoneal fibrosis: A case report.

BACKGROUND: IgG4-related disease (IgG4-RD) is a chronic fibrotic disease mediated by immunity recognized by clinicians in recent years. When the kidney is involved, it is called IgG4-related kidney disease (IgG4-RKD). IgG4-related tubulointerstitial nephritis (IgG4-TIN) is a representative manifestation of IgG4-RKD. IgG4-TIN can cause obstructive nephropathy complicated by retroperitoneal fibrosis (RPF). Cases of IgG4-TIN complicated with RPF are rare. Glucocorticoids are the first-line therapeutic medication for IgG4-RD and can significantly improve renal function. CASE SUMMARY: Herein, we r

Cancer Prevalence among Physicians in Korea: A Single Center Study.

BackgroundThere is little research regarding whether working as a physician affects cancer risk. Moreover, there is no research on cancer prevalence among physicians in Korea. This study utilized the Korea National Cancer Incidence Database to determine whether the prevalence of cancer among physicians differs from the prevalence of cancer within the general population.MethodsWe analyzed the medical records of a representative sample of 382 doctors who underwent a health examination between 2010 and 2013 at a health examination center in a Ewha Womans University Medical Center.Cancer incidence

Sciatica как нетипичное первоначальное представление множественной миеломы: отчет о деле.

ВЕРТЕБРАЛЬНОЕ участие в множественной миеломе является частой причиной заболеваемости и связано с сильной болью, деформацией позвоночника и неврологическим компромиссом. Несмотря на то, что боль в спине является широко распространенной особенностью, сицика в качестве первоначального проявления множественной миеломы является крайне редким явлением, особенно у пациентов, не имеющих истории травм или остеопоротических факторов риска. Признание таких нетипичных презентаций имеет решающее значение для своевременной диагностики и управления. ОПИСАНИЕ СЛУЧАИ: Мужчина среднего возраста без какой-либо

Совпадение в полном тексте источника
… APTT, activated partial thromboplastin time; INR, international normalized ratio. …

Global welfare burden of hematologic malignancies from 2015 to 2023.

Hematologic malignancies cause premature mortality and disability across the life course, but their welfare burden is difficult to compare across countries. We monetized global burden of disease (GBD) 2023 disability-adjusted life years (DALYs) for major hematologic malignancies in 188 countries from 2015 to 2023 using a value of lost welfare framework incorporating purchasing power parity adjusted gross domestic product (GDP), income transfer, age-specific valuation, and discounting. Global leukemia-related value of lost welfare (VLW) increased from US$1.40 trillion to US$1.70 trillion, while

Target-Specific Dermatological Adverse Event Reporting With T-Cell-Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016-2026.

BACKGROUND: T-cell-engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid-tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target-specific dermatological adverse event reporting patterns remain poorly defined. METHODS: We analysed 12,333,305 deduplicated FAERS reports from 2016Q1 to 2026Q1, including 23,386 reports exposed to ten T-cell-engaging bispecific antibodies grouped by target: CD19, CD20, BCMA, GPRC5D and DLL3. A disease-matched haematologic-oncology comparator co

Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy.

Hybrid nanocarriers have realized a growing interest in drug delivery research because of the potential of being able to treat, manage or cure diseases that previously had limited therapy or cure. Cancer is currently considered the second leading cause of death globally. This makes cancer therapy a major focus in terms of the need for efficacious and safe drug formulations that can be used to reduce the rate of morbidity and mortality globally. The major challenge encountered over the years with cancer chemotherapy is the non-selectivity of anticancer drugs, leading to severe adverse effects i

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35% improvement in progression-free survival with the all-oral combination of ixazomib plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone alone (median: 20.6 vs 14.7 months; hazard ratio: 0.74, p=0.012; median follow-up 14.7 months). The ad

Common haematological malignancies in Northeastern Nigeria: a multi-centre study of their pattern, distribution and treatment challenges.

BackgroundHaematological malignancies (HMs) are primary cancers of the blood and blood-forming organs. They are heterogeneous and of diverse clinical features, treatment protocols and prognoses. They constitute a significant source of cancer-related morbidity and mortality. Northeastern Nigeria, being the region in the country with the worst literacy rate and poverty indices, is also battling with the burden of these diseases with the limited health facilities to adequately diagnose and treat these ailments. There is paucity of a comprehensive data on HMs in the region, so this study aims to r

A 57-Year-Old Female Presenting With Cardiopulmonary Arrest Secondary to Severe Hypokalemia From a Fanconi-Like Syndrome: A Case Report.

Fanconi syndrome is a multi-factorial disorder that involves diffuse malfunction of the proximal convoluted tubule in the kidney. Renal wasting of potassium, glucose, bicarbonate, amino acids, and phosphorus characterize the condition. We report a case of a 57-year-old female who presented to our emergency department with cardiopulmonary arrest. After successful resuscitation, she had extensive workup to uncover the cause of her cardiac arrest. She had extensive negative workup but was found to have severely low potassium, prompting further evaluation. She was noted to have elevated urine pota

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematological tumor originating from the precursor of plasmacytoid dendritic cells (pDCs) with a persistent and progressive course of illness. Despite being an aggressive disease BPDCN has an initial indolent course manifested as skin lesions. Alongside or following the skin lesion, the extra-cutaneous manifestation develops and includes lymphadenopathy, splenomegaly, and hepatomegaly. The BPDCN diagnosis is mainly based on the immunophenotype.  Herein, we report the case of a 72-year-old male patient who presented with a hist

High Serum miR-361-3p Predicts Early Postdischarge Infections after Autologous Stem Cell Transplantation.

BackgroundAutologous hematopoietic stem cell transplantation (AHSCT) is currently the backbone of the treatment of multiple myeloma (MM) and relapsed and refractory lymphomas. Notably, infections contribute to over 25% of fatalities among AHSCT recipients within the initial 100 days following the procedure. In this study, we aimed to evaluate three selected miRNAs: hsa-miR-155-5p, hsa-miR-320c, and hsa-miR-361-3p, in identifying AHSCT recipients at high risk of infectious events up to 100 days post-transplantation after discharge.Materials and methodsThe study group consisted of 58 patients (4

Прогнозирующее значение SGK1: Ретроспективное исследование в одном центре.

Цель Это исследование направлено на оценку прогнозируемого значения сыворотки/глюкокортикоидной киназы 1 (SGK1) выражение в периферийных моноядерных клетках крови (PBMC) нескольких миеломных (MM) лиц, проходящих автологическую трансплантацию гематопоиетических стволовых клеток (AHSCT) по сравнению с традиционными минимальными остаточными заболеваниями (MRD) и оценками бесперебойной цепи света (SFLC). 85 Лица, которые прошли курс AHSCT. Выражение генов SGK1 измерялось в PBMC с использованием количественных ПЦР в режиме реального времени (qRT-PCR) в исходных условиях и в определенных интервалах

Determining the Relationship Between Perceptions of Nursing Care Quality and Satisfaction Status in Multicultural Patients with Hematological Malignancies.

AIM: This study aims to investigate the correlation between multicultural patients with hematologic malignancies' perceptions of nursing care and their level of satisfaction, with the objective of providing recommendations for enhancing the quality of nursing care based on the findings. METHODS: This descriptive and cross-sectional study was conducted with 140 patients aged 18 years and over who were hospitalized in the hematology and bone marrow transplantation unit between January and October 2024, who agreed to participate in the study and were able to communicate. Data were collected usin

Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Предсказатели высоко- и низкоинтенсивного лечения склероза первой линии.

КОЛИЧЕСТВО: Лекарства для лечения различных склерозов (MS) могут быть либо с высокой, либо с низкой интенсивностью. Цель этого исследования заключается в изучении прогнозов, связанных с высокоинтенсивными стратегиями обработки MS с использованием данных о коммерческих претензиях. Мы использовали коммерческие и дополнительные базы данных " Merative MarketScan " для обследования пациентов с помощью: амбулаторного диагноза MS ( " Merative MarketScan " )ICD-9/-10:: 340xx, G35.xx); заполнение ДМТ; отсутствие ДМТ 1 год, предшествующий диагностике MS с помощью DMT; и 6 Непрерывная

Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.

IntroductionThe phase 3 APOLLO study demonstrated significantly better progression-free survival (PFS) and clinical responses with daratumumab, pomalidomide, and dexamethasone (D-Pd) versus pomalidomide and dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM). On the basis of these results and those from the phase 1b EQUULEUS trial, D-Pd was approved in this patient population. In the absence of head-to-head data comparing D-Pd with further standard of care (SOC) therapies, indirect treatment comparisons (ITCs) can provide important information to help optimize treat

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.

IMPORTANCE: Clinical trial evidence used to support drug approval is typically the only information on benefits and harms that patients and clinicians can use for decision-making when novel cancer therapies become available. Various evaluations have raised concern about the uncertainty surrounding these data, and a systematic investigation of the available information on treatment outcomes for cancer drugs approved by the US Food and Drug Administration (FDA) is warranted. OBJECTIVE: To describe the clinical trial data available on treatment outcomes at the time of FDA approval of all novel c

Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.

BackgroundAlthough the use of bortezomib alone and in combination with steroids has shown efficacy in AL amyloidosis, its role in combination with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) is unknown. In this study, we evaluated bortezomib in combination with dexamethasone (BD) for induction chemotherapy prior to HDM/SCT.MethodsThis was a single-center, prospective, randomized controlled trial comparing induction therapy consisting of two BD cycles followed by HDM/SCT (BD + HDM/SCT) with HDM/SCT alone in the treatment of patients with newly diagnosed AL amyloidosis

Прогнозирование аутоиммунных заболеваний на основе глубокого обучения.

Аутоиммунные заболевания представляют собой сложную группу заболеваний, вызванных иммунной системой, ошибочно наносящей удар по тканям тела. Их этиология включает в себя множество факторов, таких, как генетика, экологические факторы и аномалии в иммунных клетках, что затрудняет прогнозирование и лечение. Т клетки как один из ключевых компонентов иммунной системы играют важнейшую роль в иммунной системе человека и оказывают значительное воздействие на патогенез аутоиммунных заболеваний. Ряд исследований показали, что рецепторы Т-клеток (ТКР) могут быть вовлечены в патогенез различных аутоиммунн